摘要
目的:探讨应用美托洛尔和卡托普利治疗扩张型心肌病(DCM)目的在于能否减轻免疫介导心肌损伤及改善慢性心室重构。方法:73例确诊为扩张型心肌病的患者,随机分3组:对照组为常规治疗;治疗1组在对照组的治疗基础上加用美托洛尔;治疗2组在治疗1组的治疗基础上同时加用卡托普利。观察治疗前后的心率(HR)、心胸比、血压、左室腔舒张末内径(LVDd)、左室射血分数(LVEF)的变化以及不良反应。结果:①治疗组治疗前后HR、心胸比与治疗前均有明显下降(P<0.01),LVDd、LVEF差异有统计学意义(P<0.05);②治疗1组无心衰组好转较心衰组更显著;治疗2组有心衰组好转较无心衰组更显著;③不良反应与药物剂量的增加有关。结论:应用美托洛尔及卡托普利对DCM的干预治疗,可以改善预后,改善扩张型心肌病的慢性心室重构。
Objective：To explore whether metoprol and captopril could alleviate the immune-mediated myocardial injury and improve chronic left ventricular remodeling of dilated cardiomyopathy（DCM）.Method：73 patients diagnosed as DCM were divided into control group,Metoprol group and Metoprol＋Captorpril group randomly.The adverse effects and the varieties of heart rate（HR）、 cardiothoracic ratio（C/T）、 blood pressure（BP）、 left ventricular end diastolic diameter（LVDd）and left ventricular ejection fraction（LVEF）had been observed before and after the treatment.Result：①The HR and C/T deceased evidently（P0.01）,while LVDd and LVEF maked prominent differences（P0.05）after the treatment with Metoprol and Captorpril.② In Metoprol treating group,the improvement of non-heart failure group was better than that of heart-failure group;while in captopril and metoprol treating group,the improvement of heart failure group was better than that of non-heart-failure group.③The adverse effects were related to the increase of drug dosage.Conclusion：The interfering treatment with metoprol and captopril can improve the prognosis and the left ventricular remodeling of DCM evidently.
出处
《临床急诊杂志》
CAS
2010年第4期214-215,218,共3页
Journal of Clinical Emergency
